Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
GRI Bio, Inc. entered into Engagement Agreement with H.C. Wainwright & Co., LLC valued at Cash fee 7.0% of gross proceeds, management fee 1.0%, non-accountable expense allowance $25,000, leg (effective 2025-12-11).
- Action
- entry
- Agreement
- underwriting
- Counterparty
- H.C. Wainwright & Co., LLC
- Value
- Cash fee 7.0% of gross proceeds, management fee 1.0%, non-accountable expense allowance $25,000, leg
- Effective
- 2025-12-11
Exact text from the filing
Pursuant to an engagement agreement (as amended, the “Engagement Agreement”) with H.C. Wainwright & Co., LLC (the “Placement Agent”), the Company agreed to pay the Placement Agent in connection with the Offering (i) a cash fee equal to 7.0% of the aggregate gross proceeds received in the Offering, (ii) a management fee equal to 1.0% of the aggregate gross proceeds received in the Offering, (iii) a non-accountable expense allowance of $25,000, (iv) reimbursement of up to $100,000 for legal fees and expenses and other out of pocket expenses and (v) up to $15,950 for the clearing expenses.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
GRI Bio, Inc. entered into Securities Purchase Agreement with certain institutional investors valued at Aggregate offering of 2,603,331 shares, 8,063,336 Pre-Funded Warrants, and 10,666,667 Series F Warra (effective 2025-12-11).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- certain institutional investors
- Value
- Aggregate offering of 2,603,331 shares, 8,063,336 Pre-Funded Warrants, and 10,666,667 Series F Warra
- Effective
- 2025-12-11
Exact text from the filing
In connection with the Offering, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors. Pursuant to the Purchase Agreement, the Company agreed not to issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or any securities convertible into or exercisable or exchangeable for shares of Common Stock or file any registration statement or prospectus, or any amendment or supplement thereto for 60 days after the closing date of the Offering, subject to certain exceptions.
View on SEC.gov